公开(公告)号：PL2850101T3

公开(公告)日：2019-10-31

申请号：PL13725298

申请日：2013-05-13

Applicant: UCB BIOPHARMA SPRL

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  ATHERFOLD PAUL ALAN ,  SARKAR KAUSHIK

IPC: C07K16/28 ,  G01N33/53

公开(公告)号：HUE043661T2

公开(公告)日：2019-08-28

申请号：HUE12761789

申请日：2012-09-10

Applicant: UCB BIOPHARMA SPRL

Inventor： HUMPHREYS DAVID PAUL ,  LIGHTWOOD DANIEL JOHN ,  TYSON KERRY LOUISE ,  KNIGHT DAVID EDWARD ORMONDE ,  HERVE KARINE JEANNINE MADELEINE ,  COMPSON JOANNE ELIZABETH ,  PAGE MATTHEW JON TIMOTHY ,  PAYNE ANDREW CHARLES ,  FISHER NICOLA LOUISE ,  MACKENZIE BRENDON ,  COX MATTHEW

IPC: C07K16/12 ,  A61K39/40 ,  A61P31/04

公开(公告)号：DK2850101T3

公开(公告)日：2019-07-15

申请号：DK13725298

申请日：2013-05-13

Applicant: UCB BIOPHARMA SPRL

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  ATHERFOLD PAUL ALAN ,  SARKAR KAUSHIK

IPC: C07K16/28 ,  G01N33/53

公开(公告)号：ES2713859T3

公开(公告)日：2019-05-24

申请号：ES08742182

申请日：2008-03-21

Applicant: BIOGEN MA INC ,  UCB BIOPHARMA SPRL

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28

Abstract: Un anticuerpo anti-CD 154 o un fragmento de unión a CD 154 del mismo, que comprende: (a) una secuencia del dominio VH de acuerdo con SEQ ID NO: 1 de la Figura 5; y (b) una secuencia de dominio VL de acuerdo con SEQ ID NO: 2 de la Figura 6.

公开(公告)号：TN2017000543A1

公开(公告)日：2019-04-12

申请号：TN2017000543

申请日：2016-07-05

Applicant: UCB BIOPHARMA SPRL

Inventor： BAKER TERENCE SEWARD ,  COURADE JEAN-PHILIPPE ,  DOWNEY PATRICK ,  KNIGHT DAVID EDWARD ORMONDE ,  MAIRET- COELLO GEORGES ,  TYSON KERRY LOUISE

IPC: C07K16/18 ,  C07K14/47

Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.

公开(公告)号：DK2125894T3

公开(公告)日：2019-03-18

申请号：DK08742182

申请日：2008-03-21

Applicant: BIOGEN MA INC ,  UCB BIOPHARMA SPRL

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28

公开(公告)号：MY166021A

公开(公告)日：2018-05-21

申请号：MYPI20093874

申请日：2008-03-21

Applicant: BIOGEN MA INC ,  UCB BIOPHARMA SPRL

Inventor： ADAMS RALPH ,  BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/00 ,  A61K39/395 ,  C12N5/10 ,  C12N15/63 ,  C12P21/02

Abstract: [0427] This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain 10 sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti- CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases 15 including those that involve undesirable immune responses that are mediated by CD 154-CD40 interactions

公开(公告)号：ECSP18000844A

公开(公告)日：2018-03-31

申请号：ECPI201800844

申请日：2018-01-05

Applicant: UCB BIOPHARMA SPRL

Inventor： BAKER TERENCE SEWARD ,  TYSON KERRY LOUISE ,  COURADE JEAN-PHILIPPE ,  MAIRET-COELLO GEORGES ,  KNIGHT DAVID EDWARD ORMONDE ,  DOWNEY PATRICK

IPC: C07K14/47 ,  C07K16/18

Abstract: La presente invención se refiere a anticuerpos de unión a Tau y fragmentos de unión de los mismos.

公开(公告)号：AU2016293118A1

公开(公告)日：2018-03-08

申请号：AU2016293118

申请日：2016-07-15

Applicant: UCB BIOPHARMA SPRL

Inventor： FINNEY HELENE MARGARET ,  RAPECKI STEPHEN EDWARD ,  TYSON KERRY LOUISE ,  WRIGHT MICHAEL JOHN

IPC: C07K16/28 ,  A61K45/06

Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.

公开(公告)号：AU2016254215A1

公开(公告)日：2017-10-26

申请号：AU2016254215

申请日：2016-04-29

Applicant: HARVARD COLLEGE ,  UCB BIOPHARMA SPRL

Inventor： WIDENMAIER SCOTT B ,  ROBERTS ELISABETH HELEN ,  MOORE ADRIAN RICHARD ,  DOYLE CARL BRENDAN ,  ADAMS RALPH ,  HERVE KARINE JEANNINE MADELEINE ,  WALES SHAUNA MHAIRI ,  TYSON KERRY LOUISE ,  HOTAMISLIGIL GÖKHAN S ,  BURAK MEHMET F ,  ENGIN FEYZA

IPC: A61K39/00

Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as "aP2") for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.